Last Updated: May 12, 2026

Profile for Japan Patent: 2024506370


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 2024506370

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
12,042,484 May 7, 2042 Fidelity Biopharma ONTRALFY tizanidine hydrochloride
12,263,158 May 7, 2042 Fidelity Biopharma ONTRALFY tizanidine hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Key insights for pharmaceutical patentability - Japan patent JP2024506370

Last updated: April 26, 2026

What does JP2024506370 claim, and how broad is its protection?

JP2024506370 is published as a Japan application that incorporates claims and coverage defined in its underlying priority patent family and regional filing strategy. Without the published claim set and the associated legal status documents for JP2024506370, a scope-and-claims analysis cannot be completed accurately, and a reliable patent-landscape map cannot be produced to business-grade standards.

What is the exact claim scope of JP2024506370 (independent and dependent claims)?

Nothing can be produced here because the claim text for JP2024506370 is not present in the provided information, and claim scope depends on the literal wording of:

  • Independent claims (core elements, functional limitations, preparation and formulation elements, and therapeutic use language)
  • Dependent claims (fallback positions that narrow scope)
  • Claim numbering and claim dependencies (determine whether limitations are cumulative or alternative)
  • Any claim amendments reflected in the publication text (post-search/prosecution changes can alter scope)

How does JP2024506370 define the product and method boundaries (composition, dose, use, process)?

Nothing can be produced because boundary-defining details (for example: molecular identity, salts/polymorphs, excipients, dose ranges, administration route, and specific uses) must be read directly from JP2024506370’s published claims. Those details are not available in the prompt.

What is the likely patent family lineage behind JP2024506370 (priorities, continuations, equivalents)?

Nothing can be produced because family lineage requires at least:

  • The published bibliographic record for JP2024506370 (priority documents and dates)
  • The international publication or granted counterparts that define the same claim set
  • Any Japan-specific amendments

None of that data is present in the prompt.

Who are the closest competitors and what do adjacent filings claim (same target, same chemistry, same indication)?

Nothing can be produced because an actionable landscape requires verified search results from Japan patent publications and/or legal-status databases, including:

  • Overlapping assignees or inventors in Japan
  • Same-structure equivalents (process-by-structure, Markush alternatives, salt/polymorph sets)
  • Same-indication filings with narrower or broader claim language
  • Expiry and term-adjustment structure in Japan for relevant family members

No search results, CPC codes, assignee names, applicant data, or claim themes were provided.

How strong is JP2024506370 against design-arounds (what claim elements are hardest to avoid)?

Nothing can be produced because strength against design-arounds is claim-text specific. The key elements that typically drive enforceability and avoidability (and would need to be extracted and compared across dependent claims) include:

  • Structural claim anchors (exact compounds vs genus definitions)
  • Functional claiming (activity thresholds, assay-defined characteristics)
  • Preparation/process constraints (critical process steps and parameters)
  • Product-form constraints (polymorph, particle size, amorphous/crystalline state)
  • Use constraints (medical indication and patient stratification language)

No claim text is available.

Where does JP2024506370 sit in the Japanese enforcement ecosystem (opposition, examination outcome, grant likelihood)?

Nothing can be produced because enforcement posture depends on procedural and legal documents (grant status, amendments, scope-of-claims post-exam, and any rejections/appeals). Those legal facts are not supplied.


Key Takeaways

  • JP2024506370’s scope, claim-by-claim boundaries, and Japan-specific landscape cannot be analyzed without the published claim set and legal/status record.
  • Any attempt to describe the claim scope or competitor landscape without verified claim text and family/legal data would be non-actionable for R&D and investment decisions.

FAQs

  1. Can you summarize JP2024506370’s independent claims without the claim text?
    No. Independent claims must be quoted and parsed from the published JP document.

  2. Can you infer JP2024506370’s scope from the title alone?
    No. Titles do not capture the literal limitations that define legal scope.

  3. Can you map the patent landscape in Japan without knowing the assignee and claim theme?
    No. Landscape mapping requires verified bibliographic and claim-content search results.

  4. Can you assess design-around resistance without knowing the exact dependent claims?
    No. Design-around resistance is driven by specific dependent fallbacks and any Markush scope.

  5. Can you provide expected enforceability or grant probability without examination history?
    No. Those conclusions require legal-status and prosecution outcome data.


References (APA)

[No citable sources were provided in the prompt.]

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.